Latest news
Goldman Sachs reiterates Neutral on Annexon stock after GBS data - Investing.comInvesting.com · Thu, 06 Aug 2026 21:07:00 GMTAnnexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 12:00:00 GMTA Maternal GBS Vaccine Just Cleared Phase 1/2. Here’s What the Trial Design Tells Us About the Regulatory Gauntlet Ahead. - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 30 Jul 2026 07:32:08 GMTHedging Their Bets: Why GBS Candidates Write Resumes Like The Twelve Days of Christmas | SSON - SSONSSON · Tue, 28 Jul 2026 12:25:08 GMT